OBJECT: The aim of this study was to evaluate long-term outcomes, including @entity5 control and neurological function, in @entity1 with cavernous @entity50 treated using Gamma Knife surgery (GKS). METHODS: One hundred fifteen @entity1 with cavernous @entity50 , excluding atypical or @entity5 , were treated with GKS between 1991 and 2003. Forty-nine @entity1 (43%) underwent GKS as the initial treatment. The mean @entity5 volume was 14 cm3, and the mean maximum and margin doses applied to the @entity5 were 27 and 13 Gy, respectively. The median follow-up period was 62 months. During the follow-up, 111 @entity1 were able to be evaluated with neuroimaging. RESULTS: The actuarial 5- and 10-year progression-free survival rates were 87 and 73%, respectively. Similarly, the actuarial 5- and 10-year focal @entity5 control rates were 94 and 92%, respectively. Regarding functional outcomes, 43 @entity1 (46%) experienced some degree of improvement, 40 (43%) remained stable, and 11 (12%) had worse preexisting or newly developed symptoms. @entity1 who underwent GKS as the initial treatment experienced significant improvement of their symptoms (p = 0.006). CONCLUSIONS: Gamma Knife surgery is a safe and effective treatment over the long term in selected @entity1 with cavernous @entity50 . @entity5 progression is more likely to occur from the lesion margin outside the treatment volume. In small to medium-sized @entity5 , GKS is an excellent alternative to resection, preserving good neurological function. For relatively large-sized @entity5 , low-dose radiosurgery (< or = 12 Gy) is acceptable for the prevention of @entity5 progression.

Long-term outcomes of Gamma Knife surgery for cavernous XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['malignant meningiomas', 'tumor', 'Tumor', 'tumors'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity50 :: ('MESH:D012851', 'Disease') :: ['sinus meningiomas']
@entity50 :: (MESH:D012851,Disease) :: ['sinus meningioma']
